antibodies against pe foxo1 (Cell Signaling Technology Inc)
Structured Review
![( A to F ) ATGL expression in breast cancer tissues by IHC staining. Representative images from para-tumor normal tissue and cancer sections (A) and quantification from 65 patients (B) are shown. Scale bars, 50 μm. The data were further analyzed by EPI levels [(C) and (D)]. The correlation of ATGL with EPI (E) and USP22 (F) was analyzed. ( G to J ) The mRNA [(G) and (H)] and protein [(I) and (J)] levels of ATGL in MDA-MB-231 cells treated with EPI (10 nM) were determined by real-time PCR and Western blotting, respectively. ( K to M ) Intracellular lipid analysis, including BODIPY [(K) and (L)], DAG (M), and FFAs (N) in WT and USP22-null MDA-MB-231 cells treated with EPI in vitro. ( O to R ) Intracellular lipid analysis in WT and USP22-null MDA-MB-231 cells isolated from the xenograft tumors as shown in . ( S ) The protein levels of USP22, <t>FOXO1,</t> and ATGL in the WT 4T1 cells, USP22 KO 4T1 cells, and the USP22 KO 4T1 cells transduced with ATGL were measured. ( T to Za ) A total of 1 × 10 5 WT, USP22 KO 4T1 cells, or USP22 KO 4T1 cells transduced with ATGL were injected into the mammary fat pad of BALB/c mice. Tumor volume (T), bioluminescence activity [(U) and (V)], and tumor weight [(W) and (X)] were measured. Lung metastases were measured by luminol fluorescence [(U) and (Y)] and H&E staining of their lung sections [(Z) and (Za)]. N = 5 each group. Pearson correlation coefficient was used as a measure of association. Statistical significance was determined by one-way ANOVA test or unpaired Student’s t test. Data are expressed as means ± SD of five independent experiments. * P < 0.05; ** P < 0.01; *** P < 0.001; ns, no statistical significance.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_8899/pmc11328899/pmc11328899__sciadv.ado1533-f3.jpg)
Antibodies Against Pe Foxo1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 45 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxo1+pe/FoxO1+Rabbit+mAb/pmc11328899-313-7-11
Average 93 stars, based on 45 article reviews
Images
1) Product Images from "Epinephrine promotes breast cancer metastasis through a ubiquitin-specific peptidase 22–mediated lipolysis circuit"
Article Title: Epinephrine promotes breast cancer metastasis through a ubiquitin-specific peptidase 22–mediated lipolysis circuit
Journal: Science Advances
doi: 10.1126/sciadv.ado1533
Figure Legend Snippet: ( A to F ) ATGL expression in breast cancer tissues by IHC staining. Representative images from para-tumor normal tissue and cancer sections (A) and quantification from 65 patients (B) are shown. Scale bars, 50 μm. The data were further analyzed by EPI levels [(C) and (D)]. The correlation of ATGL with EPI (E) and USP22 (F) was analyzed. ( G to J ) The mRNA [(G) and (H)] and protein [(I) and (J)] levels of ATGL in MDA-MB-231 cells treated with EPI (10 nM) were determined by real-time PCR and Western blotting, respectively. ( K to M ) Intracellular lipid analysis, including BODIPY [(K) and (L)], DAG (M), and FFAs (N) in WT and USP22-null MDA-MB-231 cells treated with EPI in vitro. ( O to R ) Intracellular lipid analysis in WT and USP22-null MDA-MB-231 cells isolated from the xenograft tumors as shown in . ( S ) The protein levels of USP22, FOXO1, and ATGL in the WT 4T1 cells, USP22 KO 4T1 cells, and the USP22 KO 4T1 cells transduced with ATGL were measured. ( T to Za ) A total of 1 × 10 5 WT, USP22 KO 4T1 cells, or USP22 KO 4T1 cells transduced with ATGL were injected into the mammary fat pad of BALB/c mice. Tumor volume (T), bioluminescence activity [(U) and (V)], and tumor weight [(W) and (X)] were measured. Lung metastases were measured by luminol fluorescence [(U) and (Y)] and H&E staining of their lung sections [(Z) and (Za)]. N = 5 each group. Pearson correlation coefficient was used as a measure of association. Statistical significance was determined by one-way ANOVA test or unpaired Student’s t test. Data are expressed as means ± SD of five independent experiments. * P < 0.05; ** P < 0.01; *** P < 0.001; ns, no statistical significance.
Techniques Used: Expressing, Immunohistochemistry, Real-time Polymerase Chain Reaction, Western Blot, In Vitro, Isolation, Transduction, Injection, Activity Assay, Fluorescence, Staining
Figure Legend Snippet: ( A to E ) Effect of EPI on FOXO1 protein expression in WT and USP22-null MDA-MB-231 cells without [(A) and (B)] or with MG132 treatment [(C) and (D)]. The mRNA levels of FOXO1 were analyzed by real-time RT-PCR (E). ( F to I ) Analysis of USP22, FOXO1, and ATGL expression levels by IHC in syngeneic tumor tissues as shown in . Representative images (F) (scale bars, 50 μm) and quantification data [(G) to (I)] are shown. ( J to M ) FOXO1 interaction in HEK239T cells transiently transfected with FOXO1 and USP22 (J) or USP22 truncated mutants (K) expressing plasmids and in MDA-MB-231 cells (L) or further with EPI treatment (M). WB, Western blotting. WCL, whole cell lysate. ( N to P ) Analysis of FOXO1 ubiquitination in HEK293T cells coexpressed with USP22 (N) and its mutants (O) and in USP22 WT and KO MDA-MB-231 cells (P). ( Q ) Immunoblot analysis of FOXO1 protein degradation in HEK293T cells transfected with or without USP22 ( n = 3). ( R ) Analysis of FOXO1 binding to Atgl promoter by ChIP in WT and USP22 KO MDA-MB-231 cells ( n = 5). ( S ) Reconstitution of FOXO1 expression in USP22-null MDA-MB-231 cells restored ATGL expression. ( T to Y ) Analysis of FOXO1 expression in human breast cancer tissues [(T) and (U) with para-tumor tissues as controls or (V) and (W) in EPI high and EPI low groups] as well as its correlation with USP22 (X) and EPI (Y). Scale bars, 50 μm. Pearson correlation coefficient was used as a measure of association. Statistical significance was determined by one-way ANOVA test or unpaired Student’s t test. Data are expressed as means ± SD of three or more independent experiments. * P < 0.05; ** P < 0.01; *** P < 0.001; ****P < 0.0001. ns, no statistical significance.
Techniques Used: Expressing, Quantitative RT-PCR, Transfection, Western Blot, Ubiquitin Proteomics, Binding Assay
Figure Legend Snippet: ( A and B ) Proteomic analysis of USP22 phosphorylation from HEK293T cells transfected with or without Flag-AKT. The spectra of peptides carrying phosphorylated peptides (A) and the identified phosphorylation residues of USP22 (top) and AKT (bottom) (B) are shown. ( C and D ) Analysis of phosphorylation (C) and ubiquitination (D) with USP22 and its phosphorylation mutant. ( E ) Analysis of FOXO1 interaction with USP22 and its phosphorylation mutant. ( F and G ) Analysis of protein stability of USP22 and its phosphorylation mutant ( n = 3). ( H to O ) Analysis of USP22 phosphorylation in human breast cancer by IHC. Representative images in tumor and para-controls (H) or in EPI high and EPI low groups (J) as well as the quantification from 65 patients [(I) and (K)] are shown. Scale bars, 50 μm. Statistical analyses of the correlation p-USP22-Thr 147 levels with EPI (L), total USP22 (M), FOXO1 (N), and ATGL (O) are shown. Pearson correlation coefficient was used as a measure of association. Statistical significance was determined by unpaired Student’s t test. Data are expressed as means ± SD of three or more independent experiments. ** P < 0.01; **** P < 0.0001; ns, no statistical significance.
Techniques Used: Phospho-proteomics, Transfection, Ubiquitin Proteomics, Mutagenesis
Figure Legend Snippet: ( A to E ) 4T1 TNBC cells were injected into the mammary fat pad of BALB/c mice ( N = 5 each group). Tumor volume (A), bioluminescence activity [(B) and (C)], and tumor weight [(D) and (E)] were measured. ( F to H ) The metastases of the lung were measured by luminol fluorescence [(B) and (H)] and H&E staining [(F) and (G)]. Lung tissue sections were analyzed by H&E staining [(F) and (G)]. Representative lung metastasis (F) and quantifications of five mice each group (G) are shown. ( I to L ) Lipid analysis of syngeneic tumors from (D) by lipid BODIPY [(I) and (J)], DAG (K), and FFAs (L). MFI, mean fluorescence intensity. ( M to O ) IHC analysis of USP22, FOXO1, and ATGL expression levels in syngeneic tumor tissue sections from (D). Quantification data of all five mice each group [(M) to (O)] are shown. (P) Model of targeting chronic stress–mediated cancer metastasis and lipolysis by USP22. Statistical significance was determined by one-way ANOVA test or unpaired Student’s t test. Data are expressed as means ± SD of five independent experiments. * P < 0.05; ** P < 0.01; *** P < 0.001; ****P < 0.0001; ns, no statistical significance.
Techniques Used: Injection, Activity Assay, Fluorescence, Staining, Expressing
Related Articles
other:Article Title: Dysregulated PI3K Signaling in B Cells of CVID Patients Article Snippet: Cell cultivation and activation: Survival of B-cell subpopulations was determined after cultivation of 10.000 sorted CD21 low and CD21 pos B cells in RPMI 10% FCS for 48 h. Proliferative marker Ki67 was determined after stimulation of 0.5 × 10 6 PBMCs with CpG (cat. # tlrl-2006-1, Invivogen, San Diego, CA, USA) and anti-IgM (cat. #202201, SouthernBiotech, Birmingham, AL, USA) or IL-4 (cat. #11340043, Immunotools, Friesoythe, Germany), anti-CD40 (cat. #MAB6321, R&D Systems, Minneapolic, MN, USA) and anti-IgM for 48 h. Induction of HIF1α and GLUT1 was determined after stimulation of PBMCs with anti-IgM (cat. #202214, Southern Biotech, Birmingham, AL, USA) for 40 h. Antibodies and dyes used in this study: CD3 PE-Cy7 (UCHT1 cat. #300420), CD4 BV421 (RPA-T4 cat. #300532), CD10 BV605 (HI10a cat. #312222), CD19 BV421 (HIB19) (cat. #302234), CD19 APC-Cy7 (HIB19 cat. #302218), CD21 PE-Cy7 (Bu32 cat. #354912), CD27 BV421 (M-T271 cat. #356418), CD38 PerCp-Cy5.5 (HIT2 cat. #303522), CD38 APC (HIT2 cat. #303510), IgD BV785 (IA6-2 cat. #348242), IgM APC-Cy7 (MHM-88 cat. #314520), IgM BV421 (MHM-88 cat. #314516), Lambda FITC (MHL-38 cat. #316606), HIF1α PE (546-16 cat. #359703), KI67 AF488 (ki67 cat. #350507), Zombie UV (cat. #423107) (all BioLegend, San Diego, CA); IgD FITC (cat. #203202), IgD PE (cat. #203209), IgA PE (cat. #205009) (all Southern Biotech, Birmingham, AL); IgM AF647 (cat. #109606129), IgM AF488 (cat. #109545129 (both Jackson ImmunoResearch, West Grove, PA, USA), CD21 PE (BL13) (cat. #A32536), (both Beckman Coulter, Brea, CA); Glut1 AF647 (EPR3915) (cat. #ab195020), Mitotracker Red CMXRos (cat. #ab176832) (both Abcam, Cambridge, UK); CD27 BV605 (L128 cat. #562655), S6(pS235/pS236) AF647 (N7-548 cat. #560435), IgG AF700 (G18-145 cat. #G18145), Annexin V PE (cat. #5165875X) (all BD Biosciences, La Jolla, CA, USA); mTOR(pS2448) PE (MRRBY cat. #12971842) (ebioscience, San Diego, CA, USA); AKT (pS473) AF488 (D9E cat. #4071S), FOXO1 PE (C29H4 cat. #14262), Control:Article Title: Metabolic reprogramming of human CD8 + memory T cells through loss of SIRT1 Article Snippet: After surface marker staining, cells were permeabilized and fixed using the Foxp3/Transcription Factor Fixation/Permeabilization Concentrate and Diluent kit (eBioscience). .. Intracellular GZMB-FITC (515403; BioLegend), Staining:Article Title: Metabolic reprogramming of human CD8 + memory T cells through loss of SIRT1 Article Snippet: After surface marker staining, cells were permeabilized and fixed using the Foxp3/Transcription Factor Fixation/Permeabilization Concentrate and Diluent kit (eBioscience). .. Intracellular GZMB-FITC (515403; BioLegend), |
